Objective Most small-cell lung cancers (SCLCs) are located within the central aspect of the chest and manifest as a mediastinal or hilar lymphadenopathy. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) makes it possible to perform mediastinal and hilar nodal examinations. The purpose of this study was to evaluate the performance of EBUS-TBNA in the diagnosis of SCLC. Methods The diagnostic performances of EBUS-TBNA and/or transesophageal bronchoscopic ultrasoundguided fine-needle aspiration (EUS-FNA-B/E) were calculated using the standard definitions. Patients The study consisted of a retrospective review of the medical records for all patients with histologically proven SCLC who previously underwent EBUS-TBNA and/or EUS-FNA-B/E from May 2009 to September 2014. Results The analysis was based on 161 patients and 299 aspirated specimens. The patient group included 144 males (89%); the median age was 66 years. EBUS-TBNA and/or EUS-FNA-B/E were performed in 239 mediastinal nodes, 39 hilar/interlobar nodes, and 21 lung parenchymal lesions. The median short diameter of the biopsied lesions was 17 mm. The overall sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of EBUS-TBNA and/or EUS-FNA-B/E on a per-person basis were 97.4%, 100%, 60%, 100%, and 97.5%, respectively. The corresponding values on a per-lesion basis were 91.8%, 100%, 73.0%, 100%, and 93.3%, respectively. There were no serious complications related to EBUS-TBNA. Conclusion In our series of patients with SCLC, EBUS-TBNA had an excellent diagnostic yield in the evaluation of mediastinal, hilar and lung parenchymal lesions. Thus, EBUS-TBNA could be a useful and safe diagnostic method with which to evaluate patients with SCLC.
Introduction
Small-cell lung cancers (SCLC) are the most common primary pulmonary neuroendocrine malignancy, accounting for 13% of all newly diagnosed lung cancers (1) . It is characterized by a rapid doubling time, a high growth fraction, a propensity for early metastasis, and a high sensitivity to in-itial chemotherapy (1, 2) . Most SCLCs are located within the central aspect of the chest and manifest as a mediastinal (92%) or hilar (84%) lymphadenopathy (3) . Therefore, a rapid and accurate diagnostic method that includes the mediastinal and hilar lymph nodes is important for disease detection (4) .
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive intervention that makes it possible to perform the cytopathological evaluation of mediastinal lymphadenopathy (5) . Additionally, it provides access to lung parenchymal lesions in the adjoining bronchus without endobronchial lesions. It is also able to access the hilar and interlobar lymph nodes, which are inaccessible by mediastinoscopy (6) . The excellent diagnostic performance of EBUS-TBNA in the mediastinal staging of non-small-cell lung cancer (NSCLC), based on a sensitivity of 88-93% and a negative predictive value of 76-85%, has been reported in several studies (5, (7) (8) (9) (10) (11) .
Since most SCLCs manifest as a mediastinal or hilar lymphadenopathy, EBUS-TBNA may play an important role in the diagnosis of these tumors. While a few studies have focused on the role of EBUS-TBNA in the initial diagnosis of SCLC (12, 13) , the impact of nodal station on the diagnostic performance of EBUS-TBNA in patients with SCLC has not yet been reported. Therefore, in this study we evaluated the overall diagnostic performance of EBUS-TBNA in the diagnosis of SCLC.
Materials and Methods

Patients
We retrospectively reviewed the medical records of all patients with histologically proven SCLC who had previously undergone EBUS-TBNA and/or transesophageal bronchoscopic ultrasound-guided fine-needle aspiration (EUS-FNA-B/E) at the Samsung Medical Center (a 1,961-bed referral hospital in Seoul, Korea), between May 2009 and September 2014 (14) . Patients with previously diagnosed primary lung cancer, combined-type SCLC, or small-cell carcinoma of uncertain origin were excluded from this study. All patients underwent a conventional diagnostic workup, consisting of a physical examination, laboratory investigation, sputum cytology, chest X-ray, and chest computed tomography (CT) and integrated positron emission tomography/CT scans. EBUS-TBNA and/or EUS-FNA-B/E were performed in patients with suspected SCLC who had mediastinal or hilar lymphadenopathy or a lung parenchymal lesion that was not accessible by bronchoscopy or percutaneous transthoracic needle biopsy.
The Institutional Review Board of Samsung Medical Center approved this study, including the review and publishing of information obtained from patient records (IRB no. 2014-12-107). The requirement for informed consent was waived for the use of patient medical data, as all patient information was anonymized and de-identified prior to the analysis.
EBUS-TBNA and EUS-FNA-B/E
EBUS-TBNA was performed using the standard methods described by our group in previous publications (10, 11) . Briefly, a routine endobronchial inspection was initially performed using a convex-probe ultrasound bronchoscope fitted with a linear transducer (BF-UC206F-OL8, Olympus, Tokyo, Japan). After the completion of EBUS-TBNA, the EBUS bronchoscope was re-inserted through the esophagus to assess the lymph nodes inaccessible by EBUS-TBNA; EUS-FNA-B/E was performed as needed (14) . TBNA or FNA biopsies were obtained using a dedicated 22-gauge needle (NA-201SX-4022, Olympus). All procedures were conducted with the patients under conscious sedation induced by midazolam and fentanyl. Nebulized lidocaine (4%) was used to achieve local anesthesia prior to each procedure. Bolus doses of 1.3% lidocaine were administered during the procedure, as needed. All aspirate specimens were smeared onto glass slides, fixed immediately, and sent for cytological and/or histological examination. Rapid on-site cytopathological evaluation (ROSE) was not performed.
Diagnostic standards
All aspirate samples were categorized by pathological evaluation. Immunohistochemical studies were used in difficult cases at the discretion of the pathologist (1). Each histologic and cytologic specimen was interpreted separately as positive for SCLC, positive for malignancy, or no malignancy. Malignant lymph nodes were determined by the results of EBUS-TBNA, EUS-FNA-B/E, video-assisted thoracoscopic surgery (VATS), or clinical improvement during chemotherapy.
Benignity by EBUS-TBNA was confirmed either by VATS or by clinical follow-up. In patients in whom a malignancy as detected, further determination was based the cytohistologic results of VATS, EBUS-TBNA, and EUS-FNA-B/ E, or the finding of clinically decreased lymph node size or fluorodeoxyglucose uptake after chemotherapy. Benign lymph nodes were confirmed based on benign cytopathologic results (tuberculosis, anthracosis) from VATS, EBUS-TBNA, and EUS-FNA-B/E or the results of a clinical follow-up after at least 6 months that demonstrated a lack of radiological disease progression. Lymph nodes that were not followed up by chest CT for at least 6 months were excluded.
Statistical analysis
All data are presented as the medians (IQR) or numbers (%). The sensitivity, specificity, diagnostic accuracy, positive predictive value (PPV), and negative predictive value (NPV) of EBUS-TBNA and/or EUS-FNA-B/E were calculated on a per-person basis and per-lesion basis using the standard definitions. The 95% confidence intervals (CIs) for these values were also calculated. All statistical analyses were performed using the PASW Statistics 20 software program (SPSS Inc., Chicago, USA).
Results
Patient characteristics
During the study period, among the patients with histologically proven SCLC, 179 underwent EBUS-TBNA and/ or EUS-FNA-B/E. Of these, 18 patients with previously di- Table 1 . The median age was 66 years (IQR, 60-70 years), and 144 (89%) were males. Of the 106 patients (66%) with limited-stage disease and 55 patients (34%) with extensive-stage disease, 155 (96%) underwent EBUS-TBNA, 3 (2%) underwent a combination of EBUS-TBNA and EUS-FNA-B/E, and 3 (2%) underwent EUS-FNA-B/E only. The diagnosis of SCLC was established by EBUS-TBNA (n=146, 90.7%), EUS-FNA-B/E (n=3, 1.7%), transthoracic needle biopsy (n= 4, 2.5%), bronchoscopic biopsy (n=4, 2.5%), and surgical biopsy (n=2, 1.2%).
Diagnostic performance on a per-person basis
Of the 161 patients, examined by EBUS-TBNA and/or EUS-FNA-B/E, 151 (94%) were diagnosed with SCLC and 10 (6%) were diagnosed as not having a malignancy. Among the latter group, four patients (40%) were diagnosed with malignancy by surgery (n=1) or based on the radiological response after chemotherapy (n=3). In six patients (60%), benignity was confirmed by surgery (n=2), EBUS-TBNA (n=1) or a clinical follow-up of >6 months (n=3). Culture-positive TB lymphadenopathy was diagnosed by EBUS-TBNA in one patient, but based on a bronchoscopic biopsy he was diagnosed with SCLC ( Figure) .
The overall sensitivity, specificity, NPV, PPV, and accuracy of EBUS-TBNA and/or EUS-FNA-B/E on a per-patient basis were 97.4% (95% CI, 93.1-99.2%), 100% (95% CI, 51.7-100%), 60% (95% CI, 27.4-86.3%), 100% (95% CI, 96.9-100%), 97.5% (95% CI, 95.1-99.9%), respectively (Table 2).
Diagnostic performance on a per-lesion basis
In the 161 patients, 319 lesions (298 lymph nodes, 21 lung parenchymal masses) were biopsied using EBUS-TBNA and/or EUS-FNA-B/E. Twenty lymph nodal stations lost to chest CT follow-up after at least 6 months were excluded; thus, 299 lesions (288 lymph nodes, 21 lung parenchymal masses) were included in this analysis. The median number of aspirations per lymph node or mass was 2 (IQR, 2-3) and the median size of a lymph node or mass was 17 mm (IQR, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Tissue cores were present in 295 (98.7%) aspirate samples. There were no serious complications related to EBUS-TBNA and/or EUS-FNA-B/E. The overall sensitivity, specificity, NPN, PPV, and accuracy on a per-lesion basis were 91.8% (95% CI, 87.5-94.8%), 100% (95% CI, 91.7-100%), 73.0% (95% CI, 61.2-82.3%), 100% (95% CI, 97.9-100%), 93.3% (95% CI, 89.7-95.8%), respectively (Table 3 ). There were no significant differences in the diagnostic sensitivity of EBUS-TBNA and/or EUS-FNA-B/E at each nodal station.
Discussion
In this retrospective study, the diagnostic performances of EBUS-TBNA and EBUS-FNA-B/E were evaluated in patients with histologically proven SCLC who had previously undergone one or both procedures. The overall sensitivity, specificity, NPV, PPV, and accuracy of EBUS-TBNA and/or EUS-FNA-B/E on a per-patient basis were 97.4%, 100%, 60%, 100%, and 97.5%, respectively. The excellent diagnostic performances of these techniques in patients with SCLC are consistent with the results of previous studies of patients with NSCLC (10). Moreover, there were no serious complications related to EBUS-TBNA and/or EUS-FNA-B/E. Thus, our findings confirm the accuracy and safety of EBUS-TBNA as diagnostic method.
Two studies previously reported the diagnostic yield for SCLC. According to Wada et al. in their study of 40 patients, the sensitivity, specificity, and accuracy of EBUS-TBNA for SCLC were 96.4%, 100%, and 97.2%, respectively (12) . In the study of Murakami et al., the overall diagnostic yield of EBUS-TBNA in 98 patients with suspected SCLC was 97% (13) . To the best of our knowledge, ours is the largest study to evaluate the role of EBUS-TBNA in the initial diagnosis of SCLC. The results obtained from 161 patients clearly demonstrated the excellent diagnostic performances of EBUS-TBNA. We also studied the diagnostic performance of EBUS-TBNA on per-lesion basis. The overall performances on per-lesion basis were also excellent. Although the diagnostic performances of nodal stations on 4 L and 7 were lower than those of the other nodal station, the differences were not significant.
The combined diagnostic sensitivity of bronchoscopy using endobronchial biopsy, brushing and washing is high for endobronchial disease (88%) and poor for peripheral lesions (69%) (15) . However, some SCLCs present with a huge mediastinal mass with subtle endobronchial mucosal thickening and endobronchial biopsy may fail to diagnose the disease. Therefore, the tissue acquisition for the mediastinal mass using TBNA is very important for the diagnosis of SCLC. The combined diagnostic sensitivity of bronchoscopy with use of blind TBNA and mucosal biopsy was 91% in the previous study with SCLC (16) , and the diagnostic sensitivity of this study was 97%. Considering previous studies, EBUS-TBNA alone can provide a better diagnostic performance than conventional bronchoscopy in patients with SCLC.
EBUS-TBNA was previously shown to be an effective and safe method for the tissue diagnosis of both centrally lying parenchymal lesions located close to the airways and mediastinal and hilar lymph nodes (17, 18) . In our study, all specimens that contained lung parenchymal mass were positive for SCLC. Thus, an additional application of EBUS-TBNA could be necessary to confirm parenchymal lesions inaccessible by bronchoscopy or percutaneous transthoracic needle biopsy. In our study, EUS-FNA-B/E, with or without EBUS-TBNA, was performed in six patients. Since EUS-FNA-B/E can be used to assess lesions that are inaccessible or difficult to access by EBUS-TBNA, its use can increase the diagnostic yield.
EBUS-TBNA confirmed SCLC in six patients in this study who were diagnosed with carcinoma although it had not been confirmed as SCLC by other diagnostic procedures, such as bronchoscopic biopsy (n=2) or percutaneous transthoracic needle biopsy (n=4). EBUS-TBNA provides precise information on the target lesions, including its location, shape, demarcation, and echogenicity by endobronchial ultrasound imaging (19) . Bronchoscopy and fluoroscopy enabled us to observe the location of a lesion, but not to determine its echogenicity of lesion. With EBUS-TBNA, ultrasound images can be used to target a more suspicious area of malignancy even within the same lesion. EBUS-TBNA may also allow confirmation of the histologic subtype of the tumor if this was not possible with other diagnostic methods.
There are several limitations associated with our study. First, many lymph nodes with negative EBUS-TBNA results were not subsequently confirmed by pathology following surgery. Of the 319 aspirated specimens, pathological examination identified 94 lymph nodes (29.5%) as being without malignancy. The diagnosis was surgically confirmed in only three of these specimens. In another study, benign lymphadenopathy in NSCLC was defined as the absence of changes during 12 months (20) . Because SCLC is characterized by a rapid doubling time and high growth fraction (1, 3), we defined benign lymph nodes as those in which the lack of radiological disease progression during clinical follow-up of >6 months was determined. Second, this study was a retrospective analysis. The number of examined lesions, the decision regarding which should be targeted for biopsy, and the number of passes per lesion were decided upon by several bronchoscopists with different levels of experience. In addi-tion, we did not enroll all patients with clinically suspicious SCLC; instead, all patients with histologically proven SCLC who previously underwent EBUS-TBNA were included. Therefore, the results of our study should be interpreted conservatively.
Conclusion
In our series of patients with SCLC, EBUS-TBNA had an excellent diagnostic yield for the evaluation of mediastinal, hilar and lung parenchymal lesions. It is thus considered to be a useful and safe diagnostic method for the evaluation of patients with SCLC.
